Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Goodwill (2020 - 2025)

Cytek Biosciences' Goodwill history spans 6 years, with the latest figure at $16.7 million for Q4 2025.

  • For Q4 2025, Goodwill changed 0.2% year-over-year to $16.7 million; the TTM value through Dec 2025 reached $16.7 million, changed 0.2%, while the annual FY2025 figure was $16.7 million, 0.2% changed from the prior year.
  • Goodwill reached $16.7 million in Q4 2025 per CTKB's latest filing, roughly flat from $16.7 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $19.1 million in Q1 2023 to a low of $476000.0 in Q2 2021.
  • Average Goodwill over 5 years is $13.4 million, with a median of $16.2 million recorded in 2023.
  • Peak YoY movement for Goodwill: soared 2031.09% in 2021, then fell 15.46% in 2024.
  • A 5-year view of Goodwill shows it stood at $10.1 million in 2021, then changed by 0.0% to $10.1 million in 2022, then skyrocketed by 59.53% to $16.2 million in 2023, then rose by 2.97% to $16.7 million in 2024, then rose by 0.2% to $16.7 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Goodwill are $16.7 million (Q4 2025), $16.7 million (Q3 2025), and $16.7 million (Q2 2025).